Holen Sie sich die Stockscreener-App
19.90
5.06%
-1.06
Handel nachbörslich:
19.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$20.96
Offen:
$21.2
24-Stunden-Volumen:
1.18M
Relative Volume:
0.65
Marktkapitalisierung:
$2.47B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-599.49M
KGV:
-3.9721
EPS:
-5.01
Netto-Cashflow:
$-604.32M
1W Leistung:
-0.25%
1M Leistung:
+0.71%
6M Leistung:
-21.16%
1J Leistung:
-31.80%
1-Tages-Spanne:
$19.88
$21.30
1-Wochen-Bereich:
$19.88
$21.30
52-Wochen-Spanne:
$17.05
$36.72
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
19.90 | 2.47B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from B. Riley - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5%What's Next? - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Outperform Rating from Royal Bank of Canada - MarketBeat
Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating - Marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript - MSN
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results, Misses Expectations By $0.97 EPS - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals: Promising Pipeline Amidst Cautious Financial Outlook Warrants Hold Rating - TipRanks
Arrowhead Pharmaceuticals IncOn February 10 - Smartkarma
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by abrdn plc - MarketBeat
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down After Earnings Miss - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - BioSpace
Arrowhead Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy Rating - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts - Investing.com
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines -- Shares Down After Hours - Marketscreener.com
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Reports Q1 Revenue $2.5M -February 10, 2025 at 04:16 pm EST - Marketscreener.com
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Arrowhead Pharmaceuticals Q1 2025 Earnings Preview - MSN
Arrowhead and Sarepta close $500 million licensing deal By Investing.com - Investing.com Australia
ARWR Seals Mega-Deal: $825M Cash Infusion Plus Billions in Potential Milestone Payments - StockTitan
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns - Seeking Alpha
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):